首页> 外文期刊>Gastrointestinal Endoscopy >EUS-guided pancreatic duct drainage: Ready for prime time?
【24h】

EUS-guided pancreatic duct drainage: Ready for prime time?

机译:EUS引导的胰管道排水:准备好黄酮时间?

获取原文
获取原文并翻译 | 示例
           

摘要

Background: EUS can provide access to the main pancreatic duct (MPD) for therapeutic intervention. The long-term clinical success of EUS-guided MPD interventions is unknown. Objective: To determine technical and clinical success rates, predictors of success, and long-term outcomes of EUS-guided MPD intervention. Design: Retrospective, single-center study. Setting: Tertiary-care referral center.Patients: Forty-five patients.Intervention: EUS-guided MPD stent retrieval or placement. Main Outcome Measurements: Technical and clinical success rates, adverse events, and long-term clinical outcomes. Results: Among the 45 patients, 37 had undergone failed ERCP, and 29 had surgically altered anatomy. Median follow-up after initial EUS-guided intervention was 23 months. Two patients underwent EUS for stent removal, and EUS-guided MPD stent placement was attempted in 43 patients. Technical success was achieved in 32 of 43 patients (74%) with antegrade (n = 18) or retrograde (n = 14) stent insertion. Serious adverse events occurred in 3 patients (6%). Patients underwent a median of 2 (range 1-6) follow-up procedures for revision or removal of stents, without adverse events. Complete symptom resolution occurred in 24 of 29 patients (83%) while stents were in place, including all 6 with nondilated ducts. Stents were removed in 23 patients, who were then followed for an additional median of 32 months; 4 patients had recurrent symptom's. Among the 11 failed cases, most had persistent symptoms or required surgery. Limitations: Retrospective study design, individualized patient management. Conclusion: EUS-guided MPD intervention is feasible and safe, with long-term clinical success in the majority of patients. EUS provides important treatment options, particularly in patients who would otherwise undergo surgery.
机译:背景:EU可以提供对主要胰腺导管(MPD)的进入治疗干预。 EUS引导MPD干预的长期临床成功未知。目的:确定技术和临床成功率,成功的预测因素,以及欧森德的MPD干预的长期结果。设计:回顾性,单中心研究。设置:第三级护理转诊中心.Patiants:四十五名患者。设备:EUS引导MPD支架检索或放置。主要结果测量:技术和临床成功率,不良事件和长期临床结果。结果:45例患者中,37例经历了ERCP的失败,29例手术改变解剖学。初始EUS引导干预后的中位后续时间为23个月。两名患者接受了eUS的支架去除,43名患者尝试了eus引导的MPD支架放置。技术成功是在43名患者(74%)中的32例(N = 18)或逆行(n = 14)支架插入中的32例。 3名患者发生严重的不良事件(6%)。患者经历了2(范围1-6)的中位数,用于修改或去除支架,没有不良事件。 29例患者中的24例(83%)发生完全症状分辨率,而支架已到位,包括所有6例,其中6例含有漂白管道。在23名患者中除去支架,然后随后进行32个月的额外中位数; 4名患者具有复发性症状。在11例失败的病例中,大多数有持续症状或所需的手术。限制:回顾性研究设计,个性化患者管理。结论:EUS引导的MPD干预是可行和安全的,在大多数患者中具有长期临床成功。 EUS提供重要的治疗方案,特别是在否则接受手术的患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号